Moderna mRNA Flu Shot: Early VAERS Reports After Fast Approval

Within weeks of rollout, reports naming Moderna’s new mRNA flu vaccine began appearing in the U.S. Vaccine Adverse Event Reporting System. Alternative outlets say the numbers and the types of events look familiar from earlier mRNA products. Official sources note that VAERS reports are unverified and do not prove the shot caused the problems. The gap between those two views is where the real questions sit.

Moderna mRNA Flu Shot: Early VAERS Reports After Fast Approval

What Alternative Reports Are Saying

On November 12, 2026, The People’s Voice published a piece claiming Moderna’s mFLUSIVA (the brand name for mRNA-1010) was “flooding VAERS with a record number of serious injury reports.” It listed dozens of reports within weeks of availability, including cases such as a 71-year-old woman who could no longer walk, a 71-year-old man who could not stand 17 hours later, a 74-year-old woman with partial vision loss in both eyes, a 72-year-old man with atrial fibrillation confirmed by ECG, and an 89-year-old woman who fainted and fell in a pharmacy and was taken to the emergency room. The article treats these as early warning signs and notes that VAERS is known to capture only a fraction of actual events.

Public discussion on platforms tracking VAERS has also pointed to rising counts of reports specifically tied to mFLUSIVA in the fall of 2026, with some observers describing patterns of fatigue, pain, neurological symptoms, and cardiac issues that echo earlier mRNA COVID reports. These claims rest on the raw reports themselves. They do not include full medical review or proof of causation.

For related coverage of mRNA platforms and outcomes, see The COVID Reckoning That Never Came: Excess Deaths, mRNA Shots, and Official Silence in 2026 and Pfizer vs Moderna: What a 1.96 Million Person Florida Study Shows on Deaths.

What the Phase 3 Trial Actually Showed

The main supporting data come from a large phase 3 trial published in the New England Journal of Medicine in May 2026 (the Fluent trial). Roughly 40,700 adults aged 50 and older were randomized to mRNA-1010 or a standard-dose licensed flu vaccine. Protocol-defined influenza-like illness confirmed by RT-PCR occurred in 2.0 percent of the mRNA group and 2.8 percent of the comparator group, for a relative vaccine efficacy of 26.6 percent (95 percent confidence interval 16.7 to 35.4). The trial met its pre-specified criteria for non-inferiority and superiority against the standard-dose shot.

Solicited local and systemic reactions were more common with the mRNA product: injection-site pain 65.8 percent versus 29.8 percent, fatigue 45.1 percent versus 20.3 percent, headache 37.8 percent versus 18.0 percent, and myalgia 35.4 percent versus 11.6 percent. Most were mild to moderate and lasted a median of one to two days. Serious adverse events occurred in 2.2 percent of mRNA recipients and 1.9 percent of comparator recipients over a median follow-up of about six months. Investigators judged only a handful of these as related to the vaccine. Fatal events were balanced at roughly 0.2 percent in each arm and were not assessed as vaccine-related.

FDA briefing documents and later analyses noted some numerical imbalances in the pooled data, including more reports of death coded as “unspecified cause,” anemia, and urinary tract infections in the mRNA arms. Reviewers concluded these did not form a clear causal signal after case review. No pure placebo arm was used; the comparison was to existing flu vaccines. For adults 65 and older the U.S. approval was accelerated, based in part on antibody data, with a required post-marketing effectiveness study against a high-dose comparator.

Primary trial publication: Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults, New England Journal of Medicine.

The FDA Path and Later Authorizations

In February 2026 the FDA initially issued a refuse-to-file letter for the application. The stated reason was the choice of comparator (standard-dose rather than a preferred high-dose product for older adults), not safety or the efficacy result. After further discussion the agency accepted the filing and set a goal date of August 5. The Vaccines and Related Biological Products Advisory Committee voted 9–0 that benefits outweighed risks for both the 50–64 and 65-plus age groups. The FDA approved mFLUSIVA on August 5, 2026: traditional approval for ages 50–64 and accelerated approval for 65 and older.

Health Canada authorized both mFLUSIVA and Moderna’s combination flu-COVID mRNA vaccine (mCOFLU / mRNA-1083) in early November 2026 for adults 50 and older, making Canada the first country to clear both. Common reactions listed across the studies were injection-site pain, fatigue, headache, muscle pain, joint pain, and chills, mostly mild to moderate and resolving within one to two days. No serious adverse events were assessed as related to the combination product in its pivotal study.

See also coverage of hospital mandates that arrived the same season: Emory Will Fire Staff Who Skip the Flu Shot. Why Now?.

How VAERS Works and Why the Numbers Are Contested

VAERS is a passive reporting system run by the CDC and FDA. Anyone can submit a report of an event that follows vaccination. The system is designed to detect possible signals for further investigation; it does not establish that the vaccine caused the event. Official guidance states that reports do not by themselves prove causation, and raw counts can include coincidental events, incomplete information, and multiple reports of the same case. Underreporting is widely acknowledged; estimates vary, but passive systems typically capture only a portion of actual events.

Supporters of the vaccine point to the controlled trial data showing similar serious-event rates to standard flu shots, the unanimous advisory-committee vote, and the absence of a clear new safety signal in the reviewed data. They also note that flu itself carries risks, especially for older adults, and that relative efficacy of roughly 27 percent against influenza-like illness is better than the comparator used. Critics argue that higher rates of reactogenicity, the lack of a pure placebo, accelerated approval for the oldest group, and early post-marketing reports of neurological and cardiac events warrant caution and stronger active surveillance. They also reference broader concerns about mRNA platforms that have accumulated since the COVID rollout, including documented persistence of mRNA and protein materials in some studies.

Related discussion of material persistence appears in New Paper Maps Possible Paths for mRNA Vaccine Materials to Spread Between People.

What Remains Open

The absolute number of early VAERS reports is still small relative to doses administered, and full investigation of individual cases takes time. The trial was large by flu-vaccine standards but covered one season and used an active comparator rather than placebo. Post-marketing studies for the 65-plus group are still required. Readers can examine the primary trial paper, the public VAERS data files (updated through late October 2026 at the time of writing), and the original alternative-media reporting and decide what weight to give each.

Official VAERS resources and data downloads: VAERS and CDC WONDER VAERS query.

Original source discussed: The People’s Voice, “Moderna’s ‘Fast-Tracked’ mRNA Flu Shot Is Flooding VAERS With Record Number of Serious Injury Reports,” November 12, 2026. Full article.

Disclaimer for fact-checkers: The People’s Voice is an alternative media outlet. Its reporting on raw VAERS counts and specific case descriptions should be verified against the primary VAERS database and the peer-reviewed trial publications. This article presents the claims, the controlled-trial numbers, and the regulatory record so readers can weigh them directly. It is not medical advice.


Original article: Moderna mRNA Flu Shot: Early VAERS Reports After Fast Approval on Planet Today 🚀

Automatically republished from the main blog.

What do you think? Share your opinion below – every comment matters! 😊
Please be respectful. Spamming or advertising is not allowed.

Previous Post Next Post
Share this story:

نموذج الاتصال